BIO vs NKTX · rev $651.0M vs $188.9M cap
BIO (BIO) versus Nkarta Inc (NKTX) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Nkarta Inc (NKTX) is a biotechnology company listed on NASDAQ.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported NKTX revenue for 2025-12-31 was $0. Net income was -$104.1M. NKTX currently screens at market cap $188.9M.
BIO currently screens at market cap $0. NKTX currently screens at market cap $188.9M.
Not investment advice. Open the BIO and NKTX stock pages for the full models.
Not investment advice.